









Markets
/
Stocks
/
nasdaq-ocsaw
/

Oculis Holding AG

OCSAW

View Detailed Chart

7.260USD

-0.980-12.10%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

0.00Market Cap

--P/E TTM



Oculis Holding AG

7.260

-0.980-12.10%

Overview Company Financials

Financials

Intraday

30m

Today

-12.10%

5 Days

-0.41%

1 Month

+Infinity%

6 Months

-34.95%

Year to Date

+Infinity%

1 Year

+292.43%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(2)

Buy(8)

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.192

Buy

RSI(14)

54.265

Neutral

STOCH(KDJ)(9,3,3)

83.347

Buy

ATR(14)

1.944

High Vlolatility

CCI(14)

15.407

Neutral

Williams %R

15.581

Overbought

TRIX(12,20)

4.615

Sell

StochRSI(14)

88.753

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

6.116

Buy

MA10

6.674

Buy

MA20

5.624

Buy

MA50

4.412

Buy

MA100

4.184

Buy

MA200

5.108

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Ticker SymbolOCSAW

CompanyOculis Holding AG

CEODr. Riad Sherif, M.D.

Websitehttps://oculis.com/